|Bid||0.00 x 4000|
|Ask||0.00 x 900|
|Day's Range||70.52 - 71.38|
|52 Week Range||52.83 - 71.58|
|PE Ratio (TTM)||145.67|
|Forward Dividend & Yield||1.92 (2.70%)|
|1y Target Est||N/A|
Idexx Laboratories (IDXX) incurred general and administrative expenses of $61.08 million in the second quarter, compared with $55.46 million in the second quarter of 2017. Its sales and marketing expenses increased from $87.69 million in the second quarter of 2017 to $96.25 million in the second quarter due to increased personnel-related costs. Its research and development expenses increased from $26.9 million in the second quarter of 2017 to $29.51 million in the second quarter.
Idexx Laboratories’ (IDXX) products and services cater to the companion animal, veterinary, livestock, poultry, dairy, and water testing markets. The company also sells portable electrolytes and blood gas analyzers. So far in 2018, Idexx Laboratories stock has generated more than 50.0% returns for investors.
Allergan (AGN) announced on September 19 that it plans to build its first Medical Aesthetics Innovation Center in the High-Tech Zone in Chengdu, China. The Medical Aesthetics and Innovation Center is expected to have a sophisticated training center for the healthcare professionals in the medical aesthetics field. For its medical aesthetics customers, the Center plans to feature an education and product experience space.
On September 18, Johnson & Johnson (JNJ) announced that it had submitted a new drug application to the FDA for its investigational drug, erdafitinib, for the treatment of locally advanced or metastatic UC (urothelial cancer) in patients with certain FGFR (fibroblast growth factor receptor) genetic alterations. The application is based on the findings of BLC2001, a Phase 2 study. Erdafitinib, one of the company’s key pipeline products, is expected to drive growth. The diagram below shows some of J&J’s recent pharmaceutical launches and filings expected over the next few years. In March, J&J received breakthrough therapy designation for erdafitinib from the FDA.
Allergan (AGN) is a specialty pharmaceutical company that develops a variety of products through internal programs as well as in collaboration with other companies. Allergan’s stock price has decreased nearly 0.6% to its closing price of $191.31 on September 21 compared to its closing price on September 20.
On September 23, Johnson & Johnson (JNJ) had a market capitalization of $376.8 billion, and its stock closed ~0.63% higher than the day prior. J&J was trading at a forward PE ratio of 16.8x, while its last-12-month PE ratio was 26.1x. Generally, a high forward PE is a sign of an overvalued or high-growth stock.
The Maryland biotech hopes its new superbug contract with Merck and the state of New York puts it on the national map for drug-resistant disease research.
Roche Holding AG is starting to look more like a niche player in the hottest new field in oncology, as lung-cancer study results unveiled on Monday failed to meet the benchmark set by U.S. rival Merck & Co. It’s still unclear whether and how much Roche’s drug Tecentriq can extend the lives of patients with the most common type of lung cancer when added to chemotherapy, the Basel, Switzerland-based company said in a patient trial presented Monday at the World Conference on Lung Cancer in Toronto. The results mean Roche will need to concentrate for now on less common -- and less lucrative -- types of tumors.
ILÚM will partner with health care company OpGen Inc., the New York Department of Health and the Wadsworth Center on a new "research program to detect, track and manage antimicrobial-resistant infections at healthcare institutions statewide."
This article is intended for those of you who are at the beginning of your investing journey and want to start learning about core concepts of fundamental analysis on practicalRead More...
Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.
According to Goldman Sachs analyst Jami Rubin, Merck’s (MRK) Keytruda can earn annual revenues as high as $16.0 billion by 2025. Credit Suisse expects the drug to report peak sales of about $10.0 billion by 2023. According to Trefis estimates, Keytruda is expected to attain peak sales of ~$8.0 billion going forward.
In the first half of the year, Keytruda accounted for 15.27% of Merck’s (MRK) total revenues. Keytruda earned more than 40.0% of its total sales from international markets, despite the company having launched the drug only as a monotherapy and not as a combination regimen in these markets. By the end of the first half of the year, Keytruda was earning 60.0%–65.0% of its revenues from sales to lung cancer patients.
Merck (MRK) stock has risen from $54.93 on January 2 to $70.42 on September 18—a 28.2% increase year-to-date. The performance of Merck stock has been closely related to the sales, clinical trial outcomes, and regulatory decisions for the company’s leading immuno-oncology drug, Keytruda. Approved in 13 indications and eight tumor types, Keytruda reported sales of $1.7 billion in the second quarter.
At an industry event Thursday, representatives from both Merck & Co. and Bristol-Myers Squibb stressed the importance of flexibility in real-estate assets.
GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
Galectin Therapeutics Inc. shares surged 15% in Thursday premarket trade after the company said that combining its therapy, GR-MD-02, with Keytruda, Merck & Co.'s leading cancer therapy, appeared to have better results for patients with advanced melanoma than Keytruda alone. Notably, though, results were preliminary, based on data from an early-stage, phase 1b clinical trial, and integrated results from two earlier groups of patients on lower doses of GR-MD-02 with a third, higher-dose group. Galectin said that of 14 patients across the three groups, seven had reductions in cancer tumor size, or an objective response rate of 50%. Meanwhile, Keytruda alone has response rate that ranges between 21% to 39%, noted Dr. Brendan Curti, the trial's principal investigator and the director of the Providence Cancer Institute's melanoma program. Of the trial's 14 patients, nine had their cancer improve or remain stable, or a disease control rate of 64%. The phase 1b trial also enrolled six patients with head and neck cancer, for whom a 33% objective response rate and 67% disease control rate were observed. Curti said he and others were "very encouraged" by the melanoma results, and noted that results in both cancers were better than expected for Keytruda on its own. The trial will move forward in both areas, he said, and they plan to include more patients. Galectin shares have dropped nearly 24% over the last three months, compared with a 5.1% rise in the S&P 500 and a 7.1% rise in the Dow Jones Industrial Average .
Accenture (ACN) has teamed up with Merck & Co. (MRK), one of the leading pharmaceutical giants outside the United States, to drive production, effectiveness, and innovation in the initial stages of drug development. Both companies have included Amazon’s (AMZN) AWS (Amazon Web Services) cloud computing, The involvement of the leading public cloud service provider should allow MSD to introduce a cloud-based informatics research platform to support the life sciences industry related to drug manufacturing.
Chairman, President & CEO of Merck & Co Inc (NYSE:MRK) Kenneth C Frazier sold 279,851 shares of MRK on 09/18/2018 at an average price of $70.08 a share.
Accenture (ACN) has forecast its operating margin for fiscal 2018 at 14.8%, which would be higher than its fiscal 2017 margin of 12.9%. In the past five quarters, it mostly sustained a double-digit operating margin. In the chart below, you can see its GAAP operating margin trend in the last five quarters.
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.